LIVIVO - Search results -

Search results

Result 1 - 7 of total 7

Search options

Article: Myeloid growth factor therapy for prophylaxis of febrile neutropenia in non-myeloid malignancies: appropriate doses and schedules.

Althaus, Betsy L

Journal of the National Comprehensive Cancer Network : JNCCN

2007 Volume 5, Issue 2, Page(s) 229–234

Abstract: Myeloid growth factors (MGFs) are used for the prophylaxis of febrile neutropenia and maintenance of scheduled dose delivery in the treatment of patients undergoing cancer chemotherapy. To spare cost and for patient convenience, in adults MGFs are used ... ...

Abstract	Myeloid growth factors (MGFs) are used for the prophylaxis of febrile neutropenia and maintenance of scheduled dose delivery in the treatment of patients undergoing cancer chemotherapy. To spare cost and for patient convenience, in adults MGFs are used at schedules, doses, and durations that differ from the approved prescribing information of the U.S. Food and Drug Administration. These variations include rounding doses to convenient sizes, fewer days of treatment, a shorter interval between cycles, and same-day administration with chemotherapy. Some of these variations are supported by clinical trial results and practice guidelines.
MeSH term(s)	Antineoplastic Agents/adverse effects ; Colony-Stimulating Factors/administration & dosage ; Humans ; Neoplasms/drug therapy ; Neutropenia/prevention & control
Chemical Substances	Antineoplastic Agents ; Colony-Stimulating Factors
Language	English
Publishing date	2007-01-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	2250759-0
ISSN	1540-1405
ISSN	1540-1405
DOI	10.6004/jnccn.2007.0022
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.

Krop, Ian E / Modi, Shanu / LoRusso, Patricia M / Pegram, Mark / Guardino, Ellie / Althaus, Betsy / Lu, Dan / Strasak, Alexander / Elias, Anthony

Breast cancer research : BCR

2016 Volume 18, Issue 1, Page(s) 34

Abstract: Background: In pre-clinical studies, the anti-tumor activity of T-DM1 was enhanced when combined with taxanes or pertuzumab. This phase 1b/2a study evaluated the safety/tolerability of T-DM1 + paclitaxel ± pertuzumab in HER2-positive advanced breast ... ...

Abstract	Background: In pre-clinical studies, the anti-tumor activity of T-DM1 was enhanced when combined with taxanes or pertuzumab. This phase 1b/2a study evaluated the safety/tolerability of T-DM1 + paclitaxel ± pertuzumab in HER2-positive advanced breast cancer. Methods: In phase 1b (n = 60), a 3 + 3 dose-escalation approach was used to determine the maximum tolerated dose (MTD) of T-DM1 + paclitaxel ± pertuzumab. The primary objective of phase 2a was feasibility, with 44 patients randomized to T-DM1 + paclitaxel ± pertuzumab at the MTD identified in phase 1b. Results: The MTD was T-DM1 3.6 mg/kg every three weeks (q3w) or 2.4 mg/kg weekly + paclitaxel 80 mg/m(2) weekly ± pertuzumab 840 mg loading dose followed by 420 mg q3w. Phase 2a patients had received a median of 5.0 (range: 0-10) prior therapies for advanced cancer. In phase 2a, 51.2 % received ≥12 paclitaxel doses within 15 weeks, and 14.0 % received 12 paclitaxel doses by week 12. Common all-grade adverse events (AEs) were peripheral neuropathy (90.9 %) and fatigue (79.5 %). A total of 77.3 % experienced grade ≥3 AEs, most commonly neutropenia (25.0 %) and peripheral neuropathy (18.2 %). Among the 42 phase 2a patients with measurable disease, the objective response rate (ORR) was 50.0 % (95 % confidence interval (CI) 34.6-65.4); the clinical benefit rate (CBR) was 56.8 % (95 % CI 41.6-71.0). No pharmacokinetic interactions were observed between T-DM1 and paclitaxel. Conclusions: This regimen showed clinical activity. Although there is potential for paclitaxel to be added to T-DM1 ± pertuzumab, peripheral neuropathy was common in this heavily pretreated population. Trial registration: ClinicalTrials.gov NCT00951665 . Registered August 3, 2009.
MeSH term(s)	Adult ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Female ; Humans ; Maximum Tolerated Dose ; Maytansine/administration & dosage ; Maytansine/adverse effects ; Maytansine/analogs & derivatives ; Middle Aged ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Trastuzumab
Chemical Substances	Antibodies, Monoclonal, Humanized ; Maytansine (14083FR882) ; pertuzumab (K16AIQ8CTM) ; Trastuzumab (P188ANX8CK) ; Paclitaxel (P88XT4IS4D) ; ado-trastuzumab emtansine (SE2KH7T06F)
Language	English
Publishing date	2016-03-15
Publishing country	England
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial
ZDB-ID	2015059-3
ISSN	1465-542X ; 1465-5411
ISSN (online)	1465-542X
ISSN	1465-5411
DOI	10.1186/s13058-016-0691-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 5494: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.

JAMA oncology

2020 Volume 6, Issue 3, Page(s) e193692

Abstract: Importance: Prospective assessment of treatments known to benefit patients in global clinical trials in specific racial groups is essential.: Objective: To compare the efficacy, safety, and tolerability of adding pertuzumab to trastuzumab and ... ...

Abstract	Importance: Prospective assessment of treatments known to benefit patients in global clinical trials in specific racial groups is essential. Objective: To compare the efficacy, safety, and tolerability of adding pertuzumab to trastuzumab and docetaxel vs placebo, trastuzumab, and docetaxel in Asian patients with ERBB2-positive early or locally advanced breast cancer. Design, setting, and participants: This multicenter, double-blind, placebo-controlled phase 3 trial enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) and primary tumor larger than 2 cm from March 14, 2016, to March 13, 2017. Analysis of the primary end point was performed on an intention-to-treat basis. Interventions: Before surgery, patients received 4 cycles of intravenous pertuzumab (840-mg loading dose and 420-mg maintenance doses), trastuzumab (8-mg/kg loading dose and 6-mg/kg maintenance doses), and docetaxel (75 mg/m2) or intravenous placebo, trastuzumab, and docetaxel every 3 weeks. After surgery, patients received 3 cycles of intravenous fluorouracil, epirubicin, and cyclophosphamide followed by 13 cycles of the same intravenous anti-ERBB2 therapy (pertuzumab and trastuzumab or placebo and trastuzumab) for up to 1 year. Main outcomes and measures: The primary end point was independent review committee-assessed total pathologic complete response rate. The 2-sided Cochran-Mantel-Haenszel test, stratified by disease category and hormone receptor status, was used to compare rates between treatment groups. Results: In total, 329 female patients were randomized (pertuzumab, 219; and placebo, 110; mean [SD] age, 48.8 [9.5] years). In the intention-to-treat population, total pathologic complete response rates were 39.3% (86 of 219) in the pertuzumab group and 21.8% (24 of 110) in the placebo group (difference, 17.5% [95% CI, 6.9%-28.0%]; P = .001). Of the most common grade 3 or higher adverse events, there was a higher incidence of neutropenia in the pertuzumab group (83 of 218 [38.1%] vs 36 of 110 [32.7%]). Serious adverse events were reported in 10.1% of patients (22 of 218) in the pertuzumab group and 8.2% of patients (9 of 110) in the placebo group. Conclusions and relevance: Treatment with pertuzumab, trastuzumab, and docetaxel resulted in a statistically significant improvement in the total pathologic complete response rate vs placebo, trastuzumab, and docetaxel for the neoadjuvant treatment of ERBB2-positive early or locally advanced breast cancer in Asian patients. Safety data were in line with the known pertuzumab safety profile and generally comparable between treatment groups. The PEONY trial adds to the totality of data showing the benefit of the pertuzumab regimen. Trial registration: ClinicalTrials.gov identifier: NCT02586025.
MeSH term(s)	Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Asia ; Breast Neoplasms/drug therapy ; Docetaxel/adverse effects ; Docetaxel/therapeutic use ; Double-Blind Method ; Female ; Humans ; Middle Aged ; Receptor, ErbB-2 ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal, Humanized ; Docetaxel (15H5577CQD) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; pertuzumab (K16AIQ8CTM) ; Trastuzumab (P188ANX8CK)
Language	English
Publishing date	2020-03-12
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ISSN	2374-2445
ISSN (online)	2374-2445
DOI	10.1001/jamaoncol.2019.3692
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.

Welslau, Manfred / Diéras, Veronique / Sohn, Joo-Hyuk / Hurvitz, Sara A / Lalla, Deepa / Fang, Liang / Althaus, Betsy / Guardino, Ellie / Miles, David

Cancer

2014 Volume 120, Issue 5, Page(s) 642–651

Abstract: Background: This report describes the results of an analysis of patient-reported outcomes from EMILIA (TDM4370g/BO21977), a randomized phase 3 study of the antibody-drug conjugate trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human ... ...

Abstract	Background: This report describes the results of an analysis of patient-reported outcomes from EMILIA (TDM4370g/BO21977), a randomized phase 3 study of the antibody-drug conjugate trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Methods: A secondary endpoint of the EMILIA study was time to symptom worsening (time from randomization to the first documentation of a ≥ 5-point decrease from baseline) as measured by the Trial Outcome Index Physical/Functional/Breast (TOI-PFB) subset of the Functional Assessment of Cancer Therapy-Breast questionnaire. Predefined exploratory patient-reported outcome endpoints included proportion of patients with a clinically significant improvement in symptoms (per TOI-PFB) and proportion of patients with diarrhea symptoms (per Diarrhea Assessment Scale). Results: In the T-DM1 arm, 450 of 495 patients had a baseline and ≥ 1 postbaseline TOI-PFB score versus 445 of 496 patients in the capecitabine-plus-lapatinib arm. Time to symptom worsening was delayed in the T-DM1 arm versus the capecitabine-plus-lapatinib arm (7.1 months versus 4.6 months, respectively; hazard ratio = 0.796; P = .0121). In the T-DM1 arm, 55.3% of patients developed clinically significant improvement in symptoms from baseline versus 49.4% in the capecitabine-plus-lapatinib arm (P = .0842). Although similar at baseline, the number of patients reporting diarrhea symptoms increased 1.5- to 2-fold during treatment with capecitabine and lapatinib but remained near baseline levels in the T-DM1 arm. Conclusions: Together with the EMILIA primary data, these results support the concept that T-DM1 has greater efficacy and tolerability than capecitabine plus lapatinib, which may translate into improvements in health-related quality of life.
MeSH term(s)	Adult ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/analysis ; Breast Neoplasms/chemistry ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Capecitabine ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Diarrhea/chemically induced ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/analogs & derivatives ; Health Status ; Humans ; Maytansine/administration & dosage ; Maytansine/analogs & derivatives ; Medication Adherence/statistics & numerical data ; Middle Aged ; Quality of Life ; Quinazolines/administration & dosage ; Receptor, ErbB-2/analysis ; Self Report ; Surveys and Questionnaires ; Time Factors ; Trastuzumab ; Treatment Outcome
Chemical Substances	Antibodies, Monoclonal, Humanized ; Biomarkers, Tumor ; Quinazolines ; lapatinib (0VUA21238F) ; Deoxycytidine (0W860991D6) ; Maytansine (14083FR882) ; Capecitabine (6804DJ8Z9U) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK) ; ado-trastuzumab emtansine (SE2KH7T06F) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2014-03-01
Publishing country	United States
Document type	Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.28465
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

Thuss-Patience, Peter C / Shah, Manish A / Ohtsu, Atsushi / Van Cutsem, Eric / Ajani, Jaffer A / Castro, Hugo / Mansoor, Wasat / Chung, Hyun Cheol / Bodoky, Gyorgy / Shitara, Kohei / Phillips, Gail D Lewis / van der Horst, Tina / Harle-Yge, Marie-Laurence / Althaus, Betsy L / Kang, Yoon-Koo

The Lancet. Oncology

2017 Volume 18, Issue 5, Page(s) 640–653

Abstract: Background: Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and ... ...

Abstract	Background: Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction). Methods: This is the final analysis from GATSBY, a randomised, open-label, adaptive, phase 2/3 study, done at 107 centres (28 countries worldwide). Eligible patients had HER2-positive advanced gastric cancer and progressed during or after first-line therapy. In stage one of the trial, patients were randomly assigned to treatment groups (2:2:1) to receive intravenous trastuzumab emtansine (3·6 mg/kg every 3 weeks or 2·4 mg/kg weekly) or physician's choice of a taxane (intravenous docetaxel 75 mg/m Findings: Between Sept 3, 2012, and Oct 14, 2013, 70 patients were assigned to receive trastuzumab emtansine 3·6 mg/kg every 3 weeks, 75 to receive trastuzumab emtansine 2·4 mg/kg weekly, and 37 to receive a taxane in the stage 1 part of the trial. At the pre-planned interim analysis (Oct 14, 2013), the IDMC selected trastuzumab emtansine 2·4 mg/kg weekly as the dose to proceed to stage 2. By Feb 9, 2015, a further 153 patients had been randomly assigned to receive trastuzumab emtansine 2·4 mg/kg weekly and a further 80 to receive a taxane. At data cutoff, median follow-up was 17·5 months (IQR 12·1-23·0) for the trastuzumab emtansine 2·4 mg/kg weekly group and 15·4 months (9·2-18·1) in the taxane group. Median overall survival was 7·9 months (95% CI 6·7-9·5) with trastuzumab emtansine 2·4 mg/kg weekly and 8·6 months (7·1-11·2) with taxane treatment (hazard ratio 1·15, 95% CI 0·87-1·51, one-sided p=0·86). The trastuzumab emtansine 2·4 mg/kg group had lower incidences of grade 3 or more adverse events (134 [60%] of 224 patients treated with trastuzumab emtansine vs 78 [70%] of 111 patients treated with a taxane), and similar incidences of adverse events leading to death (eight [4%] vs four [4%]), serious adverse events (65 [29%] vs 31 [28%]), and adverse events leading to treatment discontinuation (31 [14%] vs 15 [14%]) than did taxane treatment. The most common grade 3 or more adverse events in the trastuzumab emtansine 2·4 mg/kg weekly group were anaemia (59 [26%]) and thrombocytopenia (25 [11%]) compared with neutropenia (43 [39%]), and anaemia (20 [18%]), in the taxane group. The most common serious adverse events were anaemia (eight [4%]), upper gastrointestinal haemorrhage (eight [4%]), pneumonia (seven [3%]), gastric haemorrhage (six [3%]), and gastrointestinal haemorrhage (five [2%]) in the trastuzumab emtansine 2·4 mg/kg weekly group compared with pneumonia (four [4%]), febrile neutropenia (four [4%]), anaemia (three [3%]), and neutropenia (three [3%]) in the taxane group. Interpretation: Trastuzumab emtansine was not superior to taxane in patients with previously treated, HER2-positive advanced gastric cancer. There is still an unmet need in this patient group and therapeutic options remain limited. Funding: F Hoffmann-La Roche.
MeSH term(s)	Adenocarcinoma/chemistry ; Adenocarcinoma/drug therapy ; Adenocarcinoma/secondary ; Adult ; Aged ; Aged, 80 and over ; Anemia/chemically induced ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Bridged-Ring Compounds/adverse effects ; Bridged-Ring Compounds/therapeutic use ; Esophagogastric Junction ; Febrile Neutropenia/chemically induced ; Female ; Follow-Up Studies ; Gastrointestinal Hemorrhage/chemically induced ; Humans ; Intention to Treat Analysis ; Male ; Maytansine/adverse effects ; Maytansine/analogs & derivatives ; Maytansine/therapeutic use ; Middle Aged ; Pneumonia/chemically induced ; Receptor, ErbB-2/analysis ; Retreatment ; Stomach Neoplasms/chemistry ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/pathology ; Survival Rate ; Taxoids/adverse effects ; Taxoids/therapeutic use ; Thrombocytopenia/chemically induced ; Trastuzumab
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; Bridged-Ring Compounds ; Taxoids ; Maytansine (14083FR882) ; taxane (1605-68-1) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK) ; ado-trastuzumab emtansine (SE2KH7T06F)
Language	English
Publishing date	2017
Publishing country	England
Document type	Clinical Trial, Phase II ; Clinical Trial, Phase III ; Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(17)30111-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Myeloid growth factors clinical practice guidelines in oncology.

Crawford, Jeffrey / Althaus, Betsy / Armitage, James / Blayney, Douglas W / Cataland, Spero / Dale, David C / Demetri, George D / Foran, James / Heaney, Mark L / Htoy, Sally / Kloth, Dwight D / Lyman, Gary H / Michaud, Laura / Motl, Susannah / Vadhan-Raj, Saroj / Wong, Michael K

Journal of the National Comprehensive Cancer Network : JNCCN

2005 Volume 3, Issue 4, Page(s) 540–555

MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Colony-Stimulating Factors/therapeutic use ; Fever ; Filgrastim ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use ; Humans ; Medical Oncology/standards ; Neutropenia/chemically induced ; Neutropenia/drug therapy ; Neutropenia/epidemiology ; Neutropenia/prevention & control ; Polyethylene Glycols ; Recombinant Proteins ; Risk Factors
Chemical Substances	Colony-Stimulating Factors ; Recombinant Proteins ; Granulocyte Colony-Stimulating Factor (143011-72-7) ; pegfilgrastim (3A58010674) ; Polyethylene Glycols (3WJQ0SDW1A) ; sargramostim (5TAA004E22) ; Granulocyte-Macrophage Colony-Stimulating Factor (83869-56-1) ; Filgrastim (PVI5M0M1GW)
Language	English
Publishing date	2005-07-04
Publishing country	United States
Document type	Guideline ; Journal Article ; Practice Guideline
ZDB-ID	2250759-0
ISSN	1540-1405
ISSN	1540-1405
DOI	10.6004/jnccn.2005.0030
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Myeloid growth factors. Clinical practice guidelines in oncology.

Crawford, Jeffrey / Althaus, Betsy / Armitage, James / Balducci, Lodovico / Bennett, Charles / Blayney, Douglas W / Cataland, Spero R / Dale, David C / Demetri, George D / Erba, Harry P / Foran, James / Freifeld, Alison G / Heaney, Mark L / Htoy, Sally / Kloth, Dwight D / Lyman, Gary H / Messersmith, Wells A / Michaud, Laura Boehnke / Miyata, Sarah C /

Robbins, Amy / Tallman, Martin S / Vadhan-Raj, Saroj / Westervelt, Peter / Wong, Michael K

Journal of the National Comprehensive Cancer Network : JNCCN

2007 Volume 5, Issue 2, Page(s) 188–202

MeSH term(s)	Antineoplastic Agents/adverse effects ; Colony-Stimulating Factors/therapeutic use ; Humans ; Neutropenia/chemically induced ; Neutropenia/drug therapy ; Risk Assessment ; Risk Factors
Chemical Substances	Antineoplastic Agents ; Colony-Stimulating Factors
Language	English
Publishing date	2007-01-06
Publishing country	United States
Document type	Journal Article ; Practice Guideline
ZDB-ID	2250759-0
ISSN	1540-1405
ISSN	1540-1405
DOI	10.6004/jnccn.2007.0019
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Search results

Search options

Article: Myeloid growth factor therapy for prophylaxis of febrile neutropenia in non-myeloid malignancies: appropriate doses and schedules.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Article ; Online: Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article: Myeloid growth factors clinical practice guidelines in oncology.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article: Myeloid growth factors. Clinical practice guidelines in oncology.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito